Develco Pharma Schweiz AG Revenue and Competitors
Estimated Revenue & Valuation
- Develco Pharma Schweiz AG's estimated annual revenue is currently $9.4M per year.
- Develco Pharma Schweiz AG's estimated revenue per employee is $201,000
Employee Data
- Develco Pharma Schweiz AG has 47 Employees.
- Develco Pharma Schweiz AG grew their employee count by 4% last year.
Develco Pharma Schweiz AG's People
| Name | Title | Email/Phone |
|---|
Develco Pharma Schweiz AG Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Develco Pharma Schweiz AG?
Develco Pharma is a privately owned company operating in the field of development and manufacture of pharmaceutical products. We develop and produce difficult to make, innovative formulations of drugs, with the goal to improve quality of life and success of the company.
keywords:N/A
N/A
Total Funding
47
Number of Employees
$9.4M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Develco Pharma Schweiz AG News
(États-Unis), NeuroRx, Inc. (États-Unis), Jazz Pharmaceuticals, Inc. (Irlande), COMPASS (Royaume-Uni), Develco Pharma Schweiz AG (Suisse),...
... Develco pharma schweiz ag , Doughlas pharmaceuticals limited, NeuroRX, Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, LLC.,...
... panorama competitivo y crecimiento IS a una tasa compuesta anual del 16,3 % con Develco pharma schweiz ag, Doughlas Pharmaceuticals,...
Other Companies in Pratteln
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 47 | 31% | N/A |
#2 | $12.3M | 61 | 33% | N/A |
#3 | $41.3M | 125 | 14% | N/A |